Interpretation on Several Issues Concerning the Application of the «PRC Anti-Unfair Competition Law»
SPC issues the unfair competition interpretation addressing illegitimate online activities
SPC issues the unfair competition interpretation addressing illegitimate online activities
Property of securities law offenders may be used for civil compensation first.
Draft law to boost protection against systemic risks; SPC amends rules on summary procedures, service of litigation documents, small claims, and judicial confirmation; Policymakers aim to knock down localism and unify market standards
The Supreme People's Court has recently issued a significant and wide-ranging interpretation concerning how the general provisions of the PRC Civil Code should be applied. Diane Peng (Partner), Sijia Li (Counsel) and Aubrey Xiong (Associate) of Fangda Partners analyze the potential impact.
Multinational corporations with both a U.S. and China presence may increasingly find themselves caught between two legal systems as both countries implement regulations that seek to achieve diametrically opposite objectives. What are the issues and how should companies prepare and respond?
Lawyer service fee rates are required to be filed annually for the record.
Injunctive measures may be imposed on ecological and environmental tort cases
2021 regulatory trends in China, including antitrust, data privacy, sanctions, healthcare, PE/VC, capital markets, IP, banking & finance, TMT and arbitration.
Aggie Liu, Binxin Li, Yun Chen and Muzi Xuan of FenXun Partners, highlight China's 2021 legislative and enforcement developments in the intellectual property sector including how they respond to challenges posed by emerging technologies and stimulate innovative vitality, significant cases that strengthen IP protection mechanisms and standards, and what the future holds for IP in 2022
Ting Wu of Haiwen & Partners reviews the regulatory reforms taking place in China's life science and healthcare sector including legislation that has been released to encourage innovation and broaden market access to drugs, implementation of the patent linkage system, increasing antitrust enforcement pressure in the pharma sector, regulating medical devices, cosmetics and online hospitals.